Patients' vision loss, which is rare according to a new study, is also the subject of multiple lawsuits, including two filed ...

The FDA, which was originally going to make a decision by 19 August ... The site is the main supplier of fill-finish work for ...

Pharmaceutical companies behind weight loss and diabetes medication such as Ozempic are facing a lawsuit that could ...

The U.S. Food and Drug Administration (FDA) has approved Novo Nordisk's popular weight-loss drug Wegovy to treat a serious ...

GoodRx and Novo Nordisk are partnering to lower costs for Ozempic and Wegovy. Patients can use GoodRx to access ...

The CDMO will be cutting 350 jobs at its Baltimore gene therapy site after a major client’s demand shift, less than a year after Novo Holdings’ $16.5 billion acquisition.

The approval was based on Part 1 (72 week data) of the randomized, double-blind, placebo-controlled phase 3 ESSENCE trial.

New pill orforglipron was associated with a significant reduction in body weight and better cholesterol, triglycerides and blood pressure.

Novo Nordisk may pursue layoffs as its new CEO focuses on efficiency while facing intensifying obesity drug competition.

The system, from Signos, offers three- and six-month plans ($139 and $129 a month, respectively), and the company will send all of the continuous glucose monitors a patient needs, CNBC reported. Plus: ...

This is one huge reason to believe in the future of Novo Nordisk (NYSE: NVO), the Danish company behind the immensely popular Wegovy obesity treatment. Last week the company earned a new feather in ...

In a significant development for weight management, the Food and Drug Administration (FDA) announced Wednesday its approval ...